Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 5/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | CCR7 | P32248 | 2/20 | 0.31 |
| ▸ | DDIT3 | P35638 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025917 | 1.00 | CCR6 (0.37) | CCR6KCNH2HTR2AHTR2CDRD2 | |
| SCHEMBL2025241 | 0.88 | HTR2A (0.37) | CCR6KCNH2HTR2AHTR2CDRD2 | |
| SCHEMBL2025243 | 0.88 | HTR2A (0.37) | CCR6KCNH2HTR2AHTR2CDRD2 | |
| SCHEMBL2513642 | 0.81 | HTT (0.35) | KCNH2HTR2AHTR2CGCKMMP13 | |
| SCHEMBL2018407 | 0.81 | HTT (0.35) | KCNH2HTR2AHTR2CGCKMMP13 | |
| SCHEMBL2018405 | 0.81 | HTT (0.35) | KCNH2HTR2AHTR2CGCKMMP13 | |
| SCHEMBL2513636 | 0.81 | HTT (0.35) | KCNH2HTR2AHTR2CGCKMMP13 | |
| SCHEMBL2513640 | 0.81 | HTT (0.35) | KCNH2HTR2AHTR2CGCKMMP13 | |
| SCHEMBL12637305 | 0.79 | HTR2A (0.33) | CCR6KCNH2HTR2AHTR2CDRD2 | |
| SCHEMBL16762636 | 0.76 | GCK (0.63) | KCNH2GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | CCR6 2650/4885KCNH2 1011/4885HTR2A 1329/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | CCR6 2650/4885KCNH2 1011/4885HTR2A 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.